From the Food and Drug Administration.
Schwetz
Bernard A
BA
Office of the Commissioner of Food and Drugs, 5600 Fishers Lane, Rockville, MD 20857, USA.
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001943:Breast Neoplasms / Q000601:surgery*; D003452:Cryosurgery / Q000295:instrumentation*; D018226:Fibroadenoma / Q000601:surgery*; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein; D011486:Protein C / Q000627:therapeutic use*; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors*; D011994:Recombinant Proteins / Q000627:therapeutic use*; D018805:Sepsis / Q000188:drug therapy*; D012795:Sialoglycoproteins / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D000894:Anti-Inflammatory Agents, Non-Steroidal; D018501:Antirheumatic Agents; C507763:IL1RN protein, human; D053590:Interleukin 1 Receptor Antagonist Protein; D011486:Protein C; D017472:Receptors, Interleukin-1; D011994:Recombinant Proteins; D012795:Sialoglycoproteins; C421124:drotrecogin alfa activated